# A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins

Study · id `cardio:ct-nct07634484` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07634484](<https://clinicaltrials.gov/study/NCT07634484>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07634484

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07634484. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2027-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07634484, source copy `cardio:ctgov-nct07634484-2026-07-13`, retrieved 2026-10-31)
- Planned start: 2026-07-01 (anticipated) (ClinicalTrials.gov record NCT07634484, source copy `cardio:ctgov-nct07634484-2026-07-13`, retrieved 2026-10-31)
- Primary completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT07634484, source copy `cardio:ctgov-nct07634484-2026-07-13`, retrieved 2026-10-31)
- Completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT07634484, source copy `cardio:ctgov-nct07634484-2026-07-13`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT07634484, source copy `cardio:ctgov-nct07634484-2026-07-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07634484-2026-07-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins
- Condition: Hypercholesterolemia
- Intervention (Drug): Pemafibrate 0.2 mg/day
- Intervention (Drug): Pemafibrate 0.4 mg/day
- Intervention (Drug): Placebo
- Lead sponsor: Kowa Company, Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Kowa Company, Ltd. (`cardio:org-kowa-company-ltd`)

## Provenance

Content hash: 02fac772d74e30aa2efd901ba9b3aa11784d845a861358db6d5f7a9c3a43d760
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
